Loading…
Veracyte, Inc. is projected to rise to $80.51 by 2027, a +41% move from its current price of $56.97. VCYT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $55.49 | $57.03 | $58.61 | +0.10% |
| Jul 15 | $54.92 | $57.09 | $59.34 | +0.20% |
| Jul 16 | $54.50 | $57.14 | $59.92 | +0.31% |
| Jul 17 | $54.16 | $57.20 | $60.42 | +0.41% |
| Jul 18 | $53.86 | $57.26 | $60.87 | +0.51% |
| Jul 19 | $53.60 | $57.32 | $61.29 | +0.61% |
| Jul 20 | $53.37 | $57.38 | $61.69 | +0.72% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $53.37 | $57.38 | $61.69 | +0.72% |
| Week 2 | $52.16 | $57.79 | $64.02 | +1.44% |
| Week 3 | $51.34 | $58.20 | $65.98 | +2.16% |
| Week 4 | $50.71 | $58.62 | $67.75 | +2.89% |
| Week 5 | $50.21 | $59.04 | $69.41 | +3.63% |
| Week 6 | $49.80 | $59.46 | $71.00 | +4.37% |
| Week 7 | $49.44 | $59.88 | $72.53 | +5.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
It also provides the nCounter analysis system services.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc. (VCYT) is a healthcare diagnostics company with a global footprint. It carries a current price of $58.55 and a market capitalization of $4.67B, reflecting its standing in the healthcare diagnostics space. The stock is ranked 1427 by market capitalization among listed assets.
The long-run outlook provided includes a multi-year forecast showing upside potential from 2026 through 2050, with substantial growth reflected in higher annual averages and magnified upside in later years.
A major floor 47.3% below — a decisive break under it would weaken the trend.
The nearest floor, 18.7% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key VCYT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VCYT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $57.31 | Sell | $57.52 | Sell |
| MA 10 | $58.29 | Sell | $57.18 | Sell |
| MA 20 | $55.25 | Buy | $55.19 | Buy |
| MA 50 | $47.52 | Buy | $49.26 | Buy |
| MA 100 | $40.57 | Buy | $44.44 | Buy |
| MA 200 | $40.21 | Buy | $40.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.71 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 32.61 | Neutral |
| Williams %R (14) | -48.22 | Info |
| MACD (12,26,9) | -0.45 | Sell |
| ROC (12) | 5.91 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 51.78 | Neutral |
| TRIX (15) | 1.05 | Buy |
| Awesome (5,34) | 5.36 | Buy |
| Ultimate (7,14,28) | 50.03 | Neutral |
| Momentum (10) | -1.58 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 56.95 | Buy |
| ADX (14) | 35.51 | Buy |
| ATR (14) | 1.49 | Info |
The 30-day technical picture is bullish, with RSI14 at 80 indicating strong momentum. SMA50 is $42.59 and SMA200 is $38.91, suggesting a bullish setup as the short-term moving average remains above the longer-term trend. The stock trades with a defined support at $38.25 and resistance at $58.55, and its current 30-day range spans from $48.96 to $70.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.01 | $56.97 | $85.05 | 0% | Neutral | |
| $64.09 | $80.51 | $107.00 | +41% | Bullish | |
| $74.99 | $96.88 | $133.62 | +70% | Bullish | |
| $85.06 | $112.47 | $159.69 | +97% | Bullish | |
| $87.36 | $117.89 | $171.52 | +107% | Bullish | |
| $107.99 | $148.48 | $220.67 | +161% | Bullish | |
| $135.61 | $189.73 | $287.41 | +233% | Bullish | |
| $153.35 | $218.08 | $336.10 | +283% | Bullish | |
| $175.93 | $254.08 | $397.87 | +346% | Bullish | |
| $188.00 | $275.58 | $437.95 | +384% | Bullish | |
| $320.49 | $502.44 | $849.41 | +782% | Bullish | |
| $561.43 | $988.17 | $1,828.07 | +16.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.01 | $56.97 | $69.51 | +0.00% |
| August 2026 | $52.13 | $61.51 | $74.52 | +7.97% |
| September 2026 | $52.60 | $62.51 | $76.59 | +1.63% |
| October 2026 | $52.23 | $62.44 | $77.23 | -0.11% |
| November 2026 | $53.93 | $64.81 | $80.80 | +3.80% |
| December 2026 | $56.10 | $67.74 | $85.05 | +4.51% |
Click any year to see its month-by-month VCYT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Veracyte, Inc.'s 2026 outlook centres on $56.97, within a $30.01 to $85.05 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, VCYT could reach as high as $107.00, with a base case around $80.51 and support toward $64.09 — roughly +41% from $56.97. Momentum favours further upside here.
Expect VCYT to range from $74.99 to $133.62 through 2028. The $96.88 average target implies a +70% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The VCYT price prediction for 2029 points to an average of $112.47 (low $85.06, high $159.69) — a potential gain of +97% on today's $56.97. Momentum favours further upside here.
In 2030, VCYT is projected to trade between $87.36 and $171.52, averaging $117.89 — a potential gain of +107% from today's $56.97. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Veracyte, Inc.'s 2031 outlook centres on $148.48, within a $107.99 to $220.67 range. That is up +26% on the projected 2030 average. That marks a +161% change versus current levels. Momentum favours further upside here.
By 2032, VCYT could reach as high as $287.41, with a base case around $189.73 and support toward $135.61 — roughly +233% from $56.97. Buyers look set to stay in control over this stretch.
Expect VCYT to range from $153.35 to $336.10 through 2033. The $218.08 average target implies a +283% move from current prices. That is up +15% on the projected 2032 average. Momentum favours further upside here.
The VCYT price prediction for 2034 points to an average of $254.08 (low $175.93, high $397.87) — a potential gain of +346% on today's $56.97. Buyers look set to stay in control over this stretch.
In 2035, VCYT is projected to trade between $188.00 and $437.95, averaging $275.58 — a potential gain of +384% from today's $56.97. That is up +8% on the projected 2034 average. Momentum favours further upside here.
Veracyte, Inc.'s 2040 outlook centres on $502.44, within a $320.49 to $849.41 range. That is up +82% on the projected 2035 average. That marks a +782% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, VCYT could reach as high as $1,828.07, with a base case around $988.17 and support toward $561.43 — roughly +16.3x from $56.97. Momentum favours further upside here.
Investing $1,000 in VCYT today (≈ 17.553098 VCYT) could be worth
$17,345.49
+$16,345.49 (+1635%) by 2050 · US Dollar
Based on the average projected VCYT price of $988.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VCYTwould be worth at today's price.
$1,000 invested in VCYT on Jul 10, 2025 (≈ 36.337209 VCYT) would be worth
$2,070.13
+$1,070.13 (+107.0%) today · 2.07× · US Dollar
Based on a VCYT entry price of $27.52 vs. today's $56.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $57.08 | $998.07 | -0.2% |
| 1 month ago | $48.17 | $1,182.69 | +18.3% |
| 3 months ago | $31.09 | $1,832.42 | +83.2% |
| 6 months ago | $43.45 | $1,311.16 | +31.1% |
| 1 year ago | $27.52 | $2,070.13 | +107.0% |
| All time (5.0y) ago | $35.62 | $1,599.38 | +59.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VCYT forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $8.78B
The multi-year forecast shows 2026 with a min of $30.01, an average of $58.55, and a max of $88.28, with an ROI of 0 and sentiment Neutral.
From 2027 onward, the forecast turns bullish with 2027 avg $83.54, min $66.46, max $111.14, ROI 42.7, sentiment Bullish; 2028 avg $101.30, min $78.40, max $139.73, ROI 73, sentiment Bullish; 2029 avg $115.59, min $87.44, max $164.06, ROI 97.4, sentiment Bullish; 2030 avg $122.65, min $90.93, max $178.32, ROI 109.5, sentiment Bullish.
The upward trajectory continues: 2031 avg $158.56, min $115.42, max $235.44, ROI 170.8, sentiment Bullish; 2032 avg $197.88, min $141.58, max $299.41, ROI 238, sentiment Bullish; 2033 avg $225.82, min $159.00, max $347.58, ROI 285.7, sentiment Bullish; 2034 avg $270.42, min $187.51, max $422.83, ROI 361.9, sentiment Bullish; 2035 avg $287.20, min $196.26, max $455.69, ROI 390.5, sentiment Bullish.
The forecast shows substantial gains by 2040 with avg $535.32, min $342.31, max $903.08, ROI 814.3, sentiment Bullish, and by 2050 with avg $1,030.81, min $587.97, max $1,901.66, ROI 1660.6, sentiment Bullish.
These are estimates, not guarantees, and actual results can differ due to a range of market and company-specific factors.
Tap a question to reveal the answer.
The 2030 forecast shows min $90.93, avg $122.65, max $178.32, with an ROI of 109.5 and sentiment Bullish.
The forecast turns bullish after 2026, with rising averages and positive ROI from 2027 onward, though 2026 is Neutral and results are not guaranteed.
Yes. The 2050 forecast shows an average of $1,030.81 with a max of $1,901.66, implying outcomes above $1,000 are possible within the period.
2026 min $30.01, avg $58.55, max $88.28; ROI 0; sentiment Neutral.
2040 min $342.31, avg $535.32, max $903.08; ROI 814.3; sentiment Bullish.
Veracyte, Inc. Community Discussion
0Share your Veracyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.